Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2025-08-20 AGM Information
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Datum:20.08.2025
AGM Information Classification · 1% confidence The document is a formal notification regarding the exemption from preparing individual consolidated financial statements and management reports under German commercial law (HGB). It details a shareholder resolution from the Annual General Meeting (AGM) held on May 28, 2025, where the company decided to utilize the exemption provided by § 264 Abs. 3 and § 291 Abs. 1 HGB. Since this document is a regulatory disclosure of a specific corporate governance and accounting decision made at an AGM, and it does not fit into standard financial reporting categories like 10-K or IR, it is best classified as a Regulatory Filing (RNS).
2025-08-20 German
Datum:11.08.2025
Annual Report Classification · 1% confidence The document is a comprehensive 'Konzernabschluss' (Consolidated Financial Statement) and 'Konzernlagebericht' (Group Management Report) for Nidda German Topco GmbH for the fiscal year 2024. It contains detailed financial tables, segment analysis, and management commentary on business performance. As it covers a full fiscal year and provides substantive financial data, it is classified as an Annual Report (10-K equivalent in this context). FY 2024
2025-08-11 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
AGM Information Classification · 1% confidence The document text explicitly mentions 'Mitteilung gemäß § 264 Abs. 3 sowie § 291 Abs. 2 Nr. 4 HGB i.V.m. § 325 HGB (analog)' and details a resolution passed by the 'außerordentliche Hauptversammlung' (Extraordinary General Meeting) on 26.02.2025 regarding exemptions for the fiscal year 2024. It specifically discusses the approval of exemptions from preparing consolidated financial statements based on the parent company's report. This content directly relates to the formal proceedings and outcomes of a shareholder meeting, specifically concerning statutory reporting requirements and approvals. Given the options, this document is a formal announcement or record related to the Annual General Meeting (AGM) proceedings, specifically the resolution passed there. While it touches upon financial reporting exemptions (which might suggest AR or 10-K context), the core action described is the shareholder resolution ('Zustimmungsbeschluss') made at the EGM. Therefore, 'AGM Information' (AGM-R) is the most appropriate classification for documenting the outcome of a general meeting resolution.
2025-07-07 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Audit Report / Information Classification · 1% confidence The document text explicitly contains German financial statements, including a 'Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023' (Annual Financial Statements for the fiscal year from 01.01.2023 to 31.12.2023), a 'Bilanz' (Balance Sheet), and a 'Gewinn- und Verlustrechnung' (Profit and Loss Statement) for the full year 2023. It also includes an 'Anhang zum Jahresabschluss 2023' (Notes to the 2023 Annual Financial Statements) detailing accounting principles ('Bilanzierungs- und Bewertungsgrundsätze'). This content structure is characteristic of a full annual financial report, which corresponds to the definition of a 10-K (Annual Report), even though the document is in German and references German GAAP (HGB) rather than US GAAP/SEC forms directly. Given the comprehensive nature covering the entire fiscal year and including the balance sheet, P&L, and notes, it is classified as the Annual Report. FY 2023
2025-02-04 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Annual Report Classification · 1% confidence The document is titled 'Geschäftsbericht 2023' (Annual Report 2023) for STADA Arzneimittel Aktiengesellschaft. It covers the fiscal year from 01.01.2023 to 31.12.2023 and contains a CEO letter, detailed discussions on corporate culture, ESG performance, and operational highlights. While it is a segment of a larger annual report, it functions as the primary annual reporting document for the company's activities and performance. FY 2023
2025-01-21 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Annual Report Classification · 1% confidence The document is a comprehensive financial report for STADA Arzneimittel AG for the fiscal year 2022. It includes a balance sheet (Bilanz), income statement (Gewinn- und Verlustrechnung), and detailed notes to the financial statements (Anhang zum Jahresabschluss). This constitutes a full annual financial report, which is classified as a 10-K equivalent in this taxonomy. FY 2022
2024-02-14 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.